OA11870A - Synergistic effects of amlodipine and atorvastatin. - Google Patents

Synergistic effects of amlodipine and atorvastatin. Download PDF

Info

Publication number
OA11870A
OA11870A OA1200100272A OA1200100272A OA11870A OA 11870 A OA11870 A OA 11870A OA 1200100272 A OA1200100272 A OA 1200100272A OA 1200100272 A OA1200100272 A OA 1200100272A OA 11870 A OA11870 A OA 11870A
Authority
OA
OAPI
Prior art keywords
pharmaceutical composition
amlodipine
atorvastatin
blood pressure
métabolite
Prior art date
Application number
OA1200100272A
Other languages
English (en)
Inventor
Mason R Robert
Original Assignee
Mason R Robert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mason R Robert filed Critical Mason R Robert
Publication of OA11870A publication Critical patent/OA11870A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
OA1200100272A 1999-04-23 2000-04-18 Synergistic effects of amlodipine and atorvastatin. OA11870A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13066599P 1999-04-23 1999-04-23
US14530599P 1999-07-23 1999-07-23
US15112199P 1999-08-27 1999-08-27
US16659299P 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
OA11870A true OA11870A (en) 2006-03-27

Family

ID=27494873

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100272A OA11870A (en) 1999-04-23 2000-04-18 Synergistic effects of amlodipine and atorvastatin.

Country Status (30)

Country Link
EP (1) EP1173172B1 (de)
JP (1) JP2002542289A (de)
KR (1) KR20020024581A (de)
CN (1) CN1351492A (de)
AP (1) AP2001002324A0 (de)
AT (1) ATE314846T1 (de)
AU (1) AU4647000A (de)
BG (1) BG106115A (de)
BR (1) BR0010689A (de)
CA (1) CA2370639A1 (de)
CZ (1) CZ20013793A3 (de)
DE (1) DE60025344T2 (de)
DK (1) DK1173172T3 (de)
EA (1) EA004435B1 (de)
EE (1) EE200100555A (de)
ES (1) ES2256005T3 (de)
HK (1) HK1043741A1 (de)
HU (1) HUP0201016A3 (de)
IL (1) IL146085A0 (de)
IS (1) IS6118A (de)
NO (1) NO20015128L (de)
OA (1) OA11870A (de)
PE (1) PE20010055A1 (de)
PL (1) PL351408A1 (de)
PT (1) PT1173172E (de)
SK (1) SK15382001A3 (de)
SV (1) SV2002000058A (de)
TN (1) TNSN00085A1 (de)
UY (1) UY26118A1 (de)
WO (1) WO2000064443A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
CN100430057C (zh) * 2005-04-08 2008-11-05 石药集团中奇制药技术（石家庄）有限公司 左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) * 2013-08-01 2014-11-28 한국방송공사 코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
CZ20013793A3 (cs) 2002-05-15
NO20015128L (no) 2001-12-20
HUP0201016A2 (hu) 2002-07-29
EA200101112A1 (ru) 2002-06-27
TNSN00085A1 (fr) 2005-11-10
DE60025344D1 (de) 2006-03-30
EA004435B1 (ru) 2004-04-29
AP2001002324A0 (en) 2001-12-31
SV2002000058A (es) 2002-02-05
EP1173172B1 (de) 2006-01-04
WO2000064443A1 (en) 2000-11-02
NO20015128D0 (no) 2001-10-19
BR0010689A (pt) 2002-02-19
ATE314846T1 (de) 2006-02-15
ES2256005T3 (es) 2006-07-16
DE60025344T2 (de) 2006-09-28
CN1351492A (zh) 2002-05-29
DK1173172T3 (da) 2006-05-15
BG106115A (bg) 2002-11-29
PT1173172E (pt) 2006-05-31
IS6118A (is) 2001-10-19
PE20010055A1 (es) 2001-01-30
HUP0201016A3 (en) 2003-03-28
EP1173172A1 (de) 2002-01-23
UY26118A1 (es) 2001-03-16
CA2370639A1 (en) 2000-11-02
IL146085A0 (en) 2002-07-25
SK15382001A3 (sk) 2002-05-09
JP2002542289A (ja) 2002-12-10
EP1173172A4 (de) 2002-08-07
KR20020024581A (ko) 2002-03-30
WO2000064443A9 (en) 2002-08-29
AU4647000A (en) 2000-11-10
EE200100555A (et) 2002-12-16
HK1043741A1 (zh) 2002-09-27
PL351408A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
US20070037860A1 (en) Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
Hussein et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
Napoli et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension
KR100586754B1 (ko) 지단백질 산화의 억제
Osamah et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
Prasad C‐reactive protein (CRP)‐lowering agents
Libby et al. Lipid lowering improves endothelial functions
MX2007005784A (es) Efecto sinergistico de amlodipina y atorvastatina sobre la liberacion de oxido nitrico en celulas endoteliales de la aorta.
Plane et al. Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins
US6835742B2 (en) Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
OA11870A (en) Synergistic effects of amlodipine and atorvastatin.
Sherratt et al. Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length
Jorge et al. Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin
Mason A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence
Mason A rationale for combination therapy in risk factor management: a mechanistic perspective
JP2002542289A5 (de)
Fleckenstein-Grün et al. Role of calcium in arteriosclerosis—experimental evaluation of antiarteriosclerotic potencies of Ca antagonists
MXPA01010694A (en) Synergistic effects of amlodipine and atorvastatin
Lapenna et al. Antioxidant activity of amiodarone on human lipoprotein oxidation
Grieve et al. Chylomicron remnants potentiate phenylephrine-induced contractions of rat aorta by an endothelium-dependent mechanism
Stürzebecher et al. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation
Ohmori et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits
MXPA00003200A (en) Inhibtion of lipoprotein oxidation
Gaw et al. 3. Lipids and Lipid-modifying Therapy